Medpace Holdings, Inc. 10-Q

Item 1. Financial Statements MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Amounts in thousands, except share amounts) As of March 31, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 407,010 $ 245,449 Accounts receivable and unbilled, net (includes $ 1.8 million and $ 2.4 million with related parties at March 31, 2024 and December 31, 2023, respectively) 279,166 298,400 Prepaid expenses and other current assets (includes $ 0.3 million with related parties at March 31, 2024 and December 31, 2023) 58,726 49,979 Total current assets 744,902 593,828 Property and equipment, net 118,600 120,589 Operating lease right-of-use assets 138,803 144,801 Goodwill 662,396 662,396 Intangible assets, net 35,448 35,809 Deferred income taxes 75,231 74,435 Other assets 20,409 24,970 Total assets $ 1,795,789 $ 1,656,828 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable (includes $ 2.8 million and $ 3.1 million with related parties at March 31, 2024 and December 31, 2023, respectively) $ 24,402 $ 31,869 Accrued expenses 270,926 292,961 Advanced billings (includes $ 10.9 million and $ 10.1 million with related parties at March 31, 2024 and December 31, 2023, respectively) 616,697 559,860 Other current liabilities 44,620 40,441 Total current liabilities 956,645 925,131 Operating lease liabilities 136,156 142,122 Deferred income tax liability 2,364 2,404 Other long-term liabilities 29,082 28,221 Total liabilities 1,124,247 1,097,878 Commitments and contingencies (see Note 11) Shareholders’ equity: Preferred stock - $ 0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023 — — Common stock - $ 0.01 par-value; 250,000,000 shares authorized at March 31, 2024 and December 31, 2023; 30,983,185 and 30,752,292 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 310 308 Treasury stock - 70,073 and 70,573 shares at March 31, 2024 and December 31, 2023, respectively ( 12,235 ) ( 12,322 ) Additional paid-in capital 814,649 802,681 Accumulated deficit ( 119,141 ) ( 221,645 ) Accumulated other comprehensive loss ( 12,041 ) ( 10,072 ) Total shareholders’ equity 671,542 558,950 Total liabilities and shareholders’ equity $ 1,795,789 $ 1,656,828 See notes to condensed consolidated financial statements. -3- Table of Contents MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands, except per share amounts) Three Months Ended March 31, 2024 2023 Revenue, net (includes $ 12.8 million and $ 15.8 million with related parties for the three months ended March 31, 2024 and 2023, respectively) $ 511,044 $ 434,074 Operating expenses: Direct service costs, excluding depreciation and amortization 171,492 151,068 Reimbursed out-of-pocket expenses 184,410 152,817 Total direct costs 355,902 303,885 Selling, general and administrative 44,081 38,027 Depreciation 6,631 5,408 Amortization 361 550 Total operating expenses 406,975 347,870 Income from operations 104,069 86,204 Other income (expense), net: Miscellaneous income, net 4,593 687 Interest income (expense), net 4,120 ( 861 ) Total other income (expense), net 8,713 ( 174 ) Income before income taxes 112,782 86,030 Income tax provision 10,191 13,136 Net income $ 102,591 $ 72,894 Net income per share attributable to common shareholders: Basic $ 3.32 $ 2.35 Diluted $ 3.20 $ 2.27 Weighted average common shares outstanding: Basic 30,843 31,008 Diluted 32,001 32,155 See notes to condensed consolidated financial statements. -4- Table of Contents MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Amounts in thousands) Three Months Ended March 31, 2024 2023 Net income $ 102,591 $ 72,894 Other comprehensive (loss) income Foreign currency translation adjustments, net of taxes ( 1,969 ) 1,078 Comprehensive income $ 100,622 $ 73,972 See notes to condensed consolidated financial statements. -5- Table of Contents MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED) (Amounts in thousands) Common Stock Treasury Stock Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Loss Total BALANCE — December 31, 2022 $ 309 $ ( 12,497 ) $ 770,794 $ ( 359,827 ) $ ( 12,392 ) $ 386,387 Net income 72,894 72,894 Foreign currency translation 1,078 1,078 Stock-based compensation expense 5,438 5,438 Stock options exercised 4 2,459 2,463 Repurchases of common stock ( 7 ) ( 120,991 ) ( 120,998 ) Re-issuance of treasury stock 175 ( 175 ) — BALANCE — March 31, 2023 $ 306 $ ( 12,322 ) $ 778,691 $ ( 408,099 ) $ ( 11,314 ) $ 347,262 Common Stock Treasury Stock Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Loss Total BALANCE — December 31, 2023 $ 308 $ ( 12,322 ) $ 802,681 $ ( 221,645 ) $ ( 10,072 ) $ 558,950 Net income 102,591 102,591 Foreign currency translation ( 1,969 ) ( 1,969 ) Stock-based compensation expense 4,310 4,310 Stock options exercised 2 7,658 7,660 Re-issuance of treasury stock 87 ( 87 ) — BALANCE — March 31, 2024 $ 310 $ ( 12,235 ) $ 814,649 $ ( 119,141 ) $ ( 12,041 ) $ 671,542 See notes to condensed consolidated financial statements. -6- Table of Contents MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Amounts in thousands) Three Months Ended March 31, 2024 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 102,591 $ 72,894 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 6,631 5,408 Amortization 361 550 Stock-based compensation expense 4,310 5,438 Noncash lease expense 5,696 4,757 Deferred income tax benefit ( 865 ) ( 1,063 ) Other ( 4,230 ) ( 1,455 ) Changes in assets and liabilities: Accounts receivable and unbilled, net 19,116 ( 4,344 ) Prepaid expenses and other current assets ( 9,205 ) ( 10,205 ) Accounts payable ( 7,351 ) 4,457 Accrued expenses ( 21,132 ) ( 9,364 ) Advanced billings 56,837 3,311 Lease liabilities ( 5,946 ) ( 5,284 ) Other assets and liabilities, net 5,864 14,976 Net cash provided by operating activities 152,677 80,076 CASH FLOWS FROM INVESTING ACTIVITIES: Property and equipment expenditures ( 5,497 ) ( 9,513 ) Other 8,027 10 Net cash provided by (used in) investing activities 2,530 ( 9,503 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from stock option exercises 7,660 2,463 Repurchases of common stock — ( 120,146 ) Proceeds from revolving loan — 90,000 Payments on revolving loan — ( 25,000 ) Net cash provided by (used in) financing activities 7,660 ( 52,683 ) EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH ( 1,306 ) 767 INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH 161,561 18,657 CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period 245,449 28,265 CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period $ 407,010 $ 46,922 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION — Acquisition of property and equipment—non-cash $ 5,345 $ 7,216 See notes to condensed consolidated financial statements. -7- Table of Contents MEDPACE HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) March 31, 2024 (1) Basis of Presentation Description of Business Medpace Holdings, Inc. (together with its subsidiaries, “Medpace” or the “Company”), a Delaware corporation, is a global provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, post-marketing clinical support, laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia. Unaudited Interim Financial Information The interim condensed consolidated financial statements include the accounts of the Company, are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), and are unaudited. In the opinion of the Company’s management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted. The preparation of the interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results and outcomes could differ from management’s estimates and assumptions. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Share Repurchases In the fourth quarter of 2022, the Board approved a stock repurchase program of up to $ 500.0 million. The Company did no t execute any share repurchases during the three months ended March 31, 2024. During the three months ended March 31, 2023, the Company repurchased 654,787 shares for $ 120.1 million. As of March 31, 2024, the Company has remaining authorization of $ 308.8 million under the repurchase program. Repurchases under the share repurchase program are executed in the open market or negotiated transactions under trading plans put in place pursuant to Rule 10b5-1. The Company constructively retired the repurchased shares associated with these approved share repurchases, except for a small portion which were retained as Treasury Shares on the condensed consolidated statements of shareholders' equity. Retired share repurchase amounts paid in excess of par value are reflected within Accumulated deficit/Retained earnings in the Company’s condensed consolidated balance sheets. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which requires entities to enhance disclosures around segment reporting. The guidance is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures" which requires entities to enhance disclosures around income taxes. The guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures. -8- Table of Contents (2) Net Income Per Share Basic and diluted earnings or loss per share (“EPS”) are computed using the two-class method, which is an earnings allocation that determines EPS for each class of common stock and participating securities according to dividends declared and participation rights in undistributed earnings. The Company’s Restricted Stock Awards (“RSA”) are considered participating securities because they are legally issued at the date of grant and holders are entitled to receive non-forfeitable dividends during the vesting term. The computation of diluted EPS includes additional common shares, such as unvested Restricted Stock Units (“RSU”) and stock options with exercise prices less than the average market price of the Company’s common stock during the period (“in-the-money options”), which would be considered outstanding. This assumes that additional shares would have to be issued in cases where the exercise price of stock options is less than the value of the common stock being acquired because the cash proceeds received from the stock option holder would not be sufficient to acquire that same number of shares. The Company does not compute diluted EPS in cases where the inclusion of such additional shares would be anti-dilutive in effect. The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2024 and 2023 (in thousands, except for earnings per share): Three Months Ended March 31, 2024 2023 Weighted-average shares: Common shares outstanding 30,843 31,008 RSAs 13 21 Total weighted-average shares 30,856 31,029 Earnings per common share—Basic Net income $ 102,591 $ 72,894 Less: Undistributed earnings allocated to RSAs ( 45 ) ( 49 ) Net income available to common shareholders—Basic $ 102,546 $ 72,845 Net income per common share—Basic $ 3.32 $ 2.35 Basic weighted-average common shares outstanding 30,843 31,008 Effect of diluted shares 1,158 1,147 Diluted weighted-average shares outstanding 32,001 32,155 Net income per common share—Diluted $ 3.20 $ 2.27 During the three months ended March 31, 2024 and 2023, the Company had (in thousands) 0 and 10 stock options, respectively, that were excluded due to the exercise price exceeding the average fair value of the Company’s common stock during the period. (3) Fair Value Measurements The Company follows accounting guidance related to fair value measurements that defines fair value, establishes a framework for measuring fair value, and establishes a hierarchy for inputs used in measuring fair value. This hierarchy maximizes the use of “observable” inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The hierarchy specifies three levels based on the inputs, as follows: Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities. Level 2: Valuations based on directly observable inputs or unobservable inputs corroborated by market data. Level 3: Valuations based on unobservable inputs supported by little or no market activity representing management’s determination of assumptions of how market participants would price the assets or liabilities. -9- Table of Contents The fair value of financial instruments such as cash and cash equivalents, accounts receivable and unbilled, net, accounts payable, accrued expenses and advanced billings approximate their carrying amounts due to their short term maturities. The Company does not have material recurring fair value measurements as of March 31, 2024. There were no material transfers between Level 1, Level 2 or Level 3 during the three months ended March 31, 2024 and March 31, 2023. (4) Contract Assets and Contract Liabilities Contract assets and liabilities are reflected in the Company’s condensed consolidated balance sheets within the accounts reflected below. Contract Assets Accounts receivable represent amounts due from the Company’s customers who are concentrated primarily in the pharmaceutical, biotechnology, and medical device industries. Unbilled represents revenue recognized to date that has not been billed or is not yet contractually billable to the customer. In general, amounts become billable upon the achievement of negotiated contractual events, in accordance with predetermined payment schedules or when a reimbursable expense has been incurred. Amounts classified to unbilled are those billable to customers within one year from the respective balance sheet date. Accounts receivable and unbilled, net consisted of the following (in thousands): As of March 31, 2024 December 31, 2023 Accounts receivable $ 270,685 $ 275,932 Unbilled receivables 8,601 22,475 Less: allowance for doubtful accounts ( 120 ) ( 7 ) Total accounts receivable and unbilled, net $ 279,166 $ 298,400 Contract Liabilities Advanced billings represent cash received from customers, or billed amounts per an agreed upon payment schedule, in advance of services being performed or revenue being recognized. Advanced billings consisted of the following (in thousands): As of March 31, 2024 December 31, 2023 Advanced billings $ 616,697 $ 559,860 As of March 31, 2024 and December 31, 2023, the Company had approximately $ 3.2 billion and $ 2.9 billion of performance obligations remaining to be performed for active projects. -10- Table of Contents (5) Intangible Assets, Net Intangible assets, net consisted of the following (in thousands): As of March 31, 2024 December 31, 2023 Intangible assets: Finite-lived intangible assets: Carrying amount: Customer relationships $ 145,051 $ 145,051 Accumulated amortization: Customer relationships ( 141,249 ) ( 140,888 ) Total finite-lived intangible assets, net 3,802 4,163 Trade name (indefinite-lived) 31,646 31,646 Total intangible assets, net $ 35,448 $ 35,809 As of March 31, 2024, estimated amortization expense of the Company’s intangible assets for each of the next five years is as follows (in thousands): Amortization Remainder of 2024 $ 1,082 2025 946 2026 620 2027 577 2028 577 $ 3,802 (6) Accrued Expenses Accrued expenses consisted of the following (in thousands): As of March 31, 2024 December 31, 2023 Employee compensation and benefits $ 57,822 $ 75,822 Project related reimbursable expenses 199,445 205,864 Other 13,659 11,275 Total accrued expenses $ 270,926 $ 292,961 (7) Short-term Debt On September 30, 2019 (the “Closing Date”), the Company obtained an unsecured credit facility in an aggregate principal amount up to $ 50.0 million (as amended from time to time, the “Credit Facility”) through its wholly owned subsidiaries, Medpace, Inc., as borrower (the “Borrower”), and Medpace IntermediateCo, Inc., as guarantor (the “Guarantor”). On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility’s line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of revolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may -11- Table of Contents be borrowed under the facility’s line of credit to up to $ 10.0 million and extended the expiration date of revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). The Loan Agreement contains other customary loan terms, representations and warranties, and affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Loan Agreement contains certain events of default, including, among others, non-payment of principal or interest and breach of the covenants. As of March 31, 2024 and December 31, 2023, there were less than $ 0.1 million in letters of credit outstanding related to certain operating lease obligations, which are secured by the Credit Facility. (8) Leases The Company enters into leases for real estate and equipment. Real estate leases are for our corporate office space and laboratories around the world. Real estate leases have remaining lease terms of less than 1 year to 16 years. Many of the Company’s leases include options to extend the leases on a month to month basis or for set periods for up to 20 years. Many leases also include options to terminate the leases within 1 year or per other contractual terms. The components of lease expense were as follows (in thousands): Three Months Ended March 31, 2024 2023 Operating lease cost $ 7,865 $ 6,681 Variable lease cost 2,666 2,337 Supplemental cash flow information related to the leases was as follows (in thousands): Three Months Ended March 31, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 6,151 $ 5,350 Right-of-use assets obtained in exchange for lease obligations: Operating leases 904 8,419 -12- Table of Contents Supplemental balance sheet information related to the leases was as follows (in thousands): As of March 31, 2024 December 31, 2023 Operating lease right-of-use assets - related parties $ 81,041 $ 83,065 Operating lease right-of-use assets - non-related parties 57,762 61,736 Operating lease right-of-use assets $ 138,803 $ 144,801 Other current liabilities - related parties 5,882 5,730 Other current liabilities - non-related parties 16,088 16,635 Other current liabilities $ 21,970 $ 22,365 Operating lease liabilities - related parties 89,020 90,568 Operating lease liabilities - non-related parties 47,136 51,554 Operating lease liabilities 136,156 142,122 Total operating lease liabilities $ 158,126 $ 164,487 Weighted Average Remaining Lease Term (years) Operating leases 9.9 10.0 Weighted Average Discount Rate Operating leases 5.6 % 5.6 % Lease payments due related to lease liabilities as of March 31, 2024 were as follows (in thousands): Related Party Operating Leases Non-Related Parties Operating Leases Total Operating Leases Remainder of 2024 $ 8,571 $ 13,392 $ 21,963 2025 11,607 17,088 28,695 2026 11,807 13,988 25,795 2027 10,839 10,833 21,672 2028 8,609 6,035 14,644 Later years 91,669 9,422 101,091 Total lease payments 143,102 70,758 213,860 Less: imputed interest ( 48,200 ) ( 7,534 ) ( 55,734 ) Total $ 94,902 $ 63,224 $ 158,126 As of March 31, 2024, we have several additional leases with contractual obligations, which have not yet commenced, with future payments of $ 1.7 million. (9) Shareholder’s Equity and Stock-Based Compensation The Company granted 2,491 awards to employees under the 2016 Incentive Award Plan during the three months ended March 31, 2024, consisting of 2,491 RSU having five year vesting schedules. -13- Table of Contents Award Activity The following table sets forth the Company’s stock option activity: Three Months Ended March 31, 2024 Stock Options Weighted Average Exercise Price Outstanding - beginning of period 1,343,287 $ 100.75 Granted — $ — Exercised ( 148,922 ) $ 51.44 Cancelled/Forfeited/Expired — $ — Outstanding - end of period 1,194,365 $ 106.90 Exercisable - end of period 880,177 $ 88.01 The following table sets forth the Company’s RSA/RSU activity: Three Months Ended March 31, 2024 Shares/Units Outstanding and unvested - beginning of period 390,998 Granted 2,491 Vested ( 81,971 ) Forfeited ( 7,276 ) Outstanding and unvested - end of period 304,242 Stock-based compensation expense recognized in the condensed consolidated statements of operations related to all outstanding stock based compensation awards is summarized below (in thousands): Three Months Ended March 31, 2024 2023 Total direct costs $ 2,470 $ 2,940 Selling, general and administrative 1,840 2,498 Total stock-based compensation expense $ 4,310 $ 5,438 (10) Income Taxes The Company’s effective income tax rate was 9.0 % and 15.3 % for the three months ended March 31, 2024 and 2023, respectively. The Company's effective income tax rate for the three months ended March 31, 2024 varied from the U.S. statutory rate of 21 % primarily due to the impact of the state taxes, which was favorably offset by excess tax benefits recognized from share-based compensation and tax benefits related to Foreign Derived Intangible Income (FDII). (11) Commitments and Contingencies Legal Proceedings The Company is involved in legal proceedings from time to time in the ordinary course of its business, including employment claims and claims related to other business transactions. The Company cannot predict with certainty the outcome of such proceedings, but it believes that adequate reserves have been recorded and losses already recognized with respect to such proceedings, which were immaterial as of March 31, 2024 and December 31, 2023. There is a reasonable possibility that a loss exceeding amounts already recognized may be incurred related to these actions; however, the Company believes that such potential losses were immaterial as of March 31, 2024. -14- Table of Contents Purchase Commitments The Company has several minimum purchase commitments for project related supplies totaling $ 14.9 million as of March 31, 2024. In return for the commitment, Medpace receives preferential pricing. The commitments expire at various times through 2029. (12) Related Party Transactions Employee Loans The Company periodically extends short term loans or advances to employees, typically upon commencement of employment. Total receivables as a result of these employee advances of $ 0.3 million existed at March 31, 2024 and December 31, 2023, and are included in the Prepaid expenses and other current assets and Other assets line items of the condensed consolidated balance sheets, respectively, depending on the contractual repayment date. Service Agreement LIB Therapeutics LLC and subsidiaries (“LIB”) Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 6.5 million and $ 13.3 million during the three months ended March 31, 2024 and 2023, respectively, in the Company’s condensed consolidated statements of operations. As of March 31, 2024 and December 31, 2023 the Company had Advanced billings from LIB of $ 6.8 million and $ 7.6 million, respectively, in the condensed consolidated balance sheets. In addition, as of March 31, 2024 and December 31, 2023 the Company had Accounts receivable and unbilled, net from LIB of $ 0.4 million and $ 0.5 million, respectively, in the condensed consolidated balance sheets. CinRX Pharma, subsidiaries and affiliates (“CinRx”) Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from CinRx of $ 6.3 million and $ 2.5 million during the three months ended March 31, 2024 and 2023, respectively, in the Company’s condensed consolidated statements of operations. As of March 31, 2024 and December 31, 2023 the Company had Advanced billings from CinRx of $ 4.1 million and $ 2.5 million, respectively, in the condensed consolidated balance sheets. As of March 31, 2024 and December 31, 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million, respectively, in the condensed consolidated balance sheets. In addition, as of March 31, 2024 and December 31, 2023 the Company had Prepaid expenses and other current assets with CinRx of $ 0.3 million and $ 0.2 million, respectively, in the condensed consolidated balance sheets. Leased Real Estate Campus Headquarters Leases The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the lease. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10 -year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for its corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the three months ended March 31, 2024 and 2023 was $ 0.7 million and $ 0.6 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the condensed consolidated statements of operations. The Operating lease right-of-use assets at March 31, 2024 and December 31, 2023 were $ 18.9 million and $ 19.3 million, respectively, in the condensed consolidated balance sheets. The current and long-term portions of the lease liabilities at March 31, 2024 were $ 1.5 million and $ 17.7 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the condensed consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the condensed consolidated balance sheets. -15- Table of Contents In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the three months ended March 31, 2024 and 2023 was $ 1.4 million. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the condensed consolidated statements of operations. The Operating lease right-of-use assets at March 31, 2024 and December 31, 2023 were $ 51.4 million and $ 51.9 million, respectively, in the condensed consolidated balance sheets. The current and long-term portions of the lease liabilities at March 31, 2024 were $ 1.4 million and $ 63.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the condensed consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the condensed consolidated balance sheets. The Company entered into a multi-year lease agreement governing the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company assumed occupancy in 2012 and the lease expires in 2027 with the Company having one 10-year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating leases. Operating lease cost recognized for the three months ended March 31, 2024 and 2023 was $ 0.6 million. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the condensed consolidated statements of operations. The Operating lease right-of-use assets at March 31, 2024 and December 31, 2023 were $ 8.0 million and $ 8.5 million, respectively, in the condensed consolidated balance sheets. The current and long-term portions of the lease liabilities at March 31, 2024 were $ 2.1 million and $ 5.9 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the condensed consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the condensed consolidated balance sheets. The Company entered into a multi-year lease agreement governing the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company assumed occupancy in 2012 and the lease expires in 2027 with the Company having one 10-year option to extend the lease term. In the first quarter of 2024, the Company reduced the lease term in connection with a plan to replace the leased office beginning in early 2025. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the three months ended March 31, 2024 and 2023 was $ 0.7 million and $ 0.3 million. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the condensed consolidated statements of operations. The Operating lease right-of-use assets at March 31, 2024 and December 31, 2023 were $ 2.7 million and $ 3.4 million, respectively, in the condensed consolidated balance sheets. The current and long-term portions of the lease liabilities at March 31, 2024 were $ 0.9 million and $ 2.3 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the condensed consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 0.9 million and $ 2.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the condensed consolidated balance sheets. Travel Services The Company incurs expenses for travel services for company executives provided by private aviation charter companies which is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 0.3 million and $ 0.4 million during the three months ended March 31, 2024 and 2023, respectively, related to these travel services. These travel expenses are recorded in Selling, general and administrative in the Company’s condensed consolidated statements of operations. As of March 31, 2024 and December 31, 2023, the -16- Table of Contents Company had Accounts payable to the Aircraft Management Company of $ 0.1 million and $ 0.4 million, respectively, in the condensed consolidated balance sheets. (13) Entity Wide Disclosures Revenue by Category The following table disaggregates our revenue by major source (in thousands): Three Months Ended March 31, 2024 2023 Therapeutic Area Oncology $ 155,198 $ 141,951 Other 108,400 87,104 Metabolic 103,639 86,840 Cardiology 55,637 46,617 Central Nervous System 44,136 38,697 AVAI 44,034 32,865 Total revenue $ 511,044 $ 434,074 -17- Table of Contents